TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Cervera-Carrascon, V; Siurala, M; Santos, J M; Havunen, R; Tähtinen, S; Karell, P; Sorsa, S; Kanerva, A; Hemminki, A

Cervera-Carrascon, V; Siurala, M; Santos, J M; Havunen, R; Tähtinen, S; Karell, P; Sorsa, S; Kanerva, A; Hemminki, A.

Afiliación

Cervera-Carrascon V; TILT Biotherapeutics Ltd, Helsinki, Uusima, Finland.
Siurala M; Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland.
Santos JM; TILT Biotherapeutics Ltd, Helsinki, Uusima, Finland.
Havunen R; Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland.
Tähtinen S; TILT Biotherapeutics Ltd, Helsinki, Uusima, Finland.
Karell P; Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland.
Sorsa S; TILT Biotherapeutics Ltd, Helsinki, Uusima, Finland.
Kanerva A; Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland.
Hemminki A; Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland.

Oncoimmunology ; 7(5): e1412902, 2018.

Article en En | MEDLINE | ID: mdl-29721366

Palabras clave

Adenovirus; Adoptive T cell therapies; Adoptive cell therapy; Checkpoint blockade; Immunotherapy; Immunovirotherapy; Melanoma; Models of immunostimulation; Solid tumors; T cell therapy; Therapeutic antibodies; Virotherapy; anti-PD1

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Oncoimmunology Año: 2018 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google